OBJECTIVE  To monitor the distribution and drug resistance characteristics of Pseudomonas in Ningbo No. 6 Hospital from 2015 to 2024.

METHODS  Data on Pseudomonas isolates from all clinical specimens submitted by Ningbo No. 6 Hospital from 2015 to 2024 were collected. The distribution and resistance rates of strains were analyzed, with statistical comparisons conducted on annual bacterial detection rates and resistance rates. A retrospective analysis was performed on the distribution and resistance trends of Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas putida and Pseudomonas stutzeri over the years.

RESULTS  From 2015 to 2024, a total of 8 640 strains of Pseudomonas were detected, including 5 852 strains of P. aeruginosa, 1 389 strains of P. fluorescens, 633 strains of P. putida, 484 strains of P. stutzeri and 282 strains of other Pseudomonas species. The majority of Pseudomonas isolates were primarily from hand surgery （60.61%） and traumatic orthopedics （13.15%）. The proportion of P. aeruginosa from hand surgery decreased, the proportions P. fluorescens from hand surgery and traumatic orthopedics showed an upward trend （P＜0.05）. Over 97% of the major Pseudomonas isolates were detected in wound secretion specimens, and after 2018, P. fluorescens/P. putida were almost exclusively sourced from wound secretions. The resistance rates of P. aeruginosa to cephalosporins exhibited an increasing trend （P＜0.05）, with the overall resistance rate to carbapenems exceeding 5%, although it declined significantly in recent years. P. putida demonstrated a resistance rate ＞30% to piperacillin/tazobactam, and carbapenem-resistant strains emerged in 2021, reaching 3.15% by 2024, showing a notable increase （P＜0.05）. P. fluorescens exhibited a resistance rate ＞20% to piperacillin/tazobactam with a continuous upward trend （P＜0.05）, while maintaining high sensitivity to carbapenems （resistance rate: 0.51%）. P. stutzeri showed no significant changes in resistance over the decade, with a resistance rate of 0.41% to cefoperazone/sulbactam, but an increasing trend in resistance to ciprofloxacin （P＜0.05）.

CONCLUSIONS  The epidemiological and resistance characteristics of Pseudomonas undergo certain changes. Currently, vigilance is required against the resistance development and clinical threats posed by non-P. aeruginosa, alongside optimizing resistance surveillance and antibacterial drug management.